SDC1 and Miyoshi myopathy: Finally, DCA was performed according to Vickers et al. to evaluate the net benefit in MM prognosis of multivariate models incorporating CD138+ miR-25 levels with the clinically used markers of R-ISS and response to 1st line therapy.